FIGURE 5 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer

Phospho-MET expression is an indicator of MET activity post-osimertinib treatment; and proposed clinical flow diagram for treating EGFR-mutant NSCLC with evidence of MET pathway activation after osimertinib resistance. Representative phospho-MET IHC, MET FISH images and MET FISH scoring from pre- and post-osimertinib resistant tumors from patient LAT028 (multiple spatially heterogenous post-osimertinib resistant tumors shown; A) and from patient LAT021 (B). Scale bars, 50 µm. C, Clinical flow diagram for osimertinib-resistant EGFR-mutant NSCLC with evidence of MET pathway activation.